For example, in the case of ITGB2, IHC indicates that ITGB2 is only overexpressed in gliomas and prostate cancers whereas RNA-seq identifies ITGB2 elevation in breast cancer, glioma, head and neck cancer, renal cancer and stomach cancer. This evidence concerns the gene ITGB2 and prostate carcinoma.